HALO Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of -31.34% compared to Halozyme Therapeutics, Inc.'s net margin of 20.83%. Halozyme Therapeutics, Inc.'s return on equity of 91.5% beat Johnson & Johnson's return on equity of 34.46%.

Halozyme Therapeutics, Inc. has a consensus price target of $84.89, signalling upside risk potential of 31.03%. On the other hand Johnson & Johnson has an analysts' consensus of $241.08 which suggests that it could fall by -0.81%. Given that Halozyme Therapeutics, Inc. has higher upside potential than Johnson & Johnson, analysts believe Halozyme Therapeutics, Inc. is more attractive than Johnson & Johnson.

Halozyme Therapeutics, Inc. has a beta of 1.031, which suggesting that the stock is 3.116% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.337, suggesting its less volatile than the S&P 500 by 66.29%.

Halozyme Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.15% to investors and pays a quarterly dividend of $1.30 per share. Halozyme Therapeutics, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Halozyme Therapeutics, Inc. quarterly revenues are $451.8M, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Halozyme Therapeutics, Inc.'s net income of -$141.6M is lower than Johnson & Johnson's net income of $5.1B. Notably, Halozyme Therapeutics, Inc.'s price-to-earnings ratio is 25.52x while Johnson & Johnson's PE ratio is 21.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics, Inc. is 5.59x versus 6.24x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -31.34% compared to Halozyme Therapeutics, Inc.'s net margin of 34.4%. Halozyme Therapeutics, Inc.'s return on equity of 91.5% beat Eli Lilly & Co.'s return on equity of 104.39%.

Halozyme Therapeutics, Inc. has a consensus price target of $84.89, signalling upside risk potential of 31.03%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,209.21 which suggests that it could grow by 29.25%. Given that Halozyme Therapeutics, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Halozyme Therapeutics, Inc. is more attractive than Eli Lilly & Co..

Halozyme Therapeutics, Inc. has a beta of 1.031, which suggesting that the stock is 3.116% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.506, suggesting its less volatile than the S&P 500 by 49.45%.

Halozyme Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.68% to investors and pays a quarterly dividend of $1.73 per share. Halozyme Therapeutics, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Halozyme Therapeutics, Inc. quarterly revenues are $451.8M, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Halozyme Therapeutics, Inc.'s net income of -$141.6M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Halozyme Therapeutics, Inc.'s price-to-earnings ratio is 25.52x while Eli Lilly & Co.'s PE ratio is 40.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics, Inc. is 5.59x versus 12.82x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Skye Bioscience, Inc. has a net margin of -31.34% compared to Halozyme Therapeutics, Inc.'s net margin of --. Halozyme Therapeutics, Inc.'s return on equity of 91.5% beat Skye Bioscience, Inc.'s return on equity of -124.87%.

Halozyme Therapeutics, Inc. has a consensus price target of $84.89, signalling upside risk potential of 31.03%. On the other hand Skye Bioscience, Inc. has an analysts' consensus of $8.25 which suggests that it could grow by 1081.95%. Given that Skye Bioscience, Inc. has higher upside potential than Halozyme Therapeutics, Inc., analysts believe Skye Bioscience, Inc. is more attractive than Halozyme Therapeutics, Inc..

Halozyme Therapeutics, Inc. has a beta of 1.031, which suggesting that the stock is 3.116% more volatile than S&P 500. In comparison Skye Bioscience, Inc. has a beta of 2.866, suggesting its more volatile than the S&P 500 by 186.628%.

Halozyme Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Skye Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Halozyme Therapeutics, Inc. pays -- of its earnings as a dividend. Skye Bioscience, Inc. pays out -- of its earnings as a dividend.

Halozyme Therapeutics, Inc. quarterly revenues are $451.8M, which are larger than Skye Bioscience, Inc. quarterly revenues of --. Halozyme Therapeutics, Inc.'s net income of -$141.6M is lower than Skye Bioscience, Inc.'s net income of -$14.4M. Notably, Halozyme Therapeutics, Inc.'s price-to-earnings ratio is 25.52x while Skye Bioscience, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics, Inc. is 5.59x versus 476.49x for Skye Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Stryker Corp. has a net margin of -31.34% compared to Halozyme Therapeutics, Inc.'s net margin of 11.84%. Halozyme Therapeutics, Inc.'s return on equity of 91.5% beat Stryker Corp.'s return on equity of 15.17%.

Halozyme Therapeutics, Inc. has a consensus price target of $84.89, signalling upside risk potential of 31.03%. On the other hand Stryker Corp. has an analysts' consensus of $425.08 which suggests that it could grow by 28.21%. Given that Halozyme Therapeutics, Inc. has higher upside potential than Stryker Corp., analysts believe Halozyme Therapeutics, Inc. is more attractive than Stryker Corp..

Halozyme Therapeutics, Inc. has a beta of 1.031, which suggesting that the stock is 3.116% more volatile than S&P 500. In comparison Stryker Corp. has a beta of 0.919, suggesting its less volatile than the S&P 500 by 8.094%.

Halozyme Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker Corp. offers a yield of 1.03% to investors and pays a quarterly dividend of $0.88 per share. Halozyme Therapeutics, Inc. pays -- of its earnings as a dividend. Stryker Corp. pays out 40.48% of its earnings as a dividend. Stryker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Halozyme Therapeutics, Inc. quarterly revenues are $451.8M, which are smaller than Stryker Corp. quarterly revenues of $7.2B. Halozyme Therapeutics, Inc.'s net income of -$141.6M is lower than Stryker Corp.'s net income of $849M. Notably, Halozyme Therapeutics, Inc.'s price-to-earnings ratio is 25.52x while Stryker Corp.'s PE ratio is 39.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics, Inc. is 5.59x versus 5.14x for Stryker Corp.. Usually stocks with elevated PS ratios are considered overvalued.